Upcoming Research Opportunities

Open opportunities (fellowships, awards, training, research, funding, career, etc.) of interest to NEALS members can be found here. Please contact Christina Smith, NEALS Communications Coordinator, at csmith@neals.org to submit an announcement for posting on the website.

Neals logo

We are hiring a postdoctoral researcher!
An exciting opportunity to join our new project on MRI-based imaging biomarker development in ALS. The appointment will be at the Center for Magnetic Resonance Research (CMRR) at the University of Minnesota. The CMRR is one of the world’s premier magnetic resonance imaging facilities, with considerable expertise in imaging physics, engineering, and clinical research. Further details and a formal application link are available at

https://hr.myu.umn.edu/jobs/ext/359206

CVs and/or informal inquiries about the position may be emailed to Pramod Pisharady at email hidden; JavaScript is required before submitting a formal application.


Due date for nominations is January 15, 2025

Please submit your application through our new application portal here.

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) in partnership with ALS Finding a Cure® (ALSFAC) and FightMND is issuing a request for applications for the ALS Scholars in Therapeutics Program to empower young investigators to learn how to develop new treatments for people living with ALS.

This two-year program is designed to engage clinician-scientists and post-doctoral fellows to gain training and experience in therapy development for ALS at their home institution with an optional industry experience in year two. All ALS Scholars will be part of the broader ALS global community. We believe strongly in identifying, supporting, and mentoring the next generation of researchers and are continuing this tradition through the ALS Scholars in Therapeutics Program.


Award Details

  • 2 years of funding to support a clinician-scientist or post-doctoral fellow working in the ALS field anywhere in the world.
  • $150,000 USD award/funding year (inclusive of maximum 15% indirect costs)
  • Recipient must commit at least 75% effort to the proposed ALS research plan

Eligibility

  • Applications from clinician scientists and postdoctoral fellows focused on translational research.
  • Candidates with Ph.D. or M.D. with a strong publication record. International applicants are encouraged to apply.
  • The ALS-focused proposal must have a strong scientific rationale and should be largely developed by the candidate with guidance from his/her mentor.
  • Eligibility for this award is based on the date the candidate attained their degree/ qualification. For MDs, scholars will be considered if they have completed their specialist qualification (i.e., US Residency; Fellowship of the Royal Australasian College of Physicians, etc.) For PhDs they can be no more than 5 years post- degree.

Available resources: NEALS Biorepository, Target ALS post-mortem Tissue Bank, PRO-ACT, Answer ALS resources e.g. IPSC lines banked at Cedar Sinai, the Answer ALS Data portal, etc.

Budget

The ALS Scholars in Therapeutics will be awarded $150,000 USD per year (inclusive of direct and maximum 15% indirect costs) for a maximum of 2 years. These funds can be used for salary support, personnel, and/or supplies relevant to the outlined project. Year one funds will be provided by the Healey & AMG Center philanthropic fund.

Application

Full application will require the following:

  1. Administrative information: signatures from the applicant and organization acknowledging the terms and conditions of the award
  2. Scientific abstract: (300-word maximum) and lay description (150-word maximum)
  3. Research Proposal: focused on a translational effort in the ALS field (5-page maximum not including references) must include specific aims, significance, innovation, and experimental plan
  4. Timeline & Milestones
  5. Bibliography
  6. Career plan: outline of applicant’s training plans and career goals (one-page maximum)
  7. List of other funding sources for the applicant
  8. Two letters of reference: One letter must be from the applicant’s primary mentor
  9. NIH-style biographical sketch for the applicant and mentor
  10. Budget (in $USD) and budget justification: including key personnel

Review Criteria

Applications will be reviewed and scored based on the following five criteria:

  1. Candidate: Strong publication track record, evidence of independent thinking, and a creative approach to problem-solving. For clinicians,applicants should demonstrate capabilities as a clinician scientist based on prior achievements.
  2. Mentor: Ideally a principal investigator committed and actively working within ALS or related field.
  3. Project Feasibility: While preliminary data is not essential for the application, sufficient supporting data for the proposed aims is required to ensure that the project is feasible and can be completed within the two-year time frame.
  4. Scientific Rigor and Reproducibility: the research proposed must be well thought through, include details of experimental design, blinding, power calculations, and approaches to promote reproducibility including validation of key reagents. In addition, the applicant should state how they will share their findings, data, reagents with the scientific community.
  5. Research Environment: Quality and nature of training provided by mentor as well as institutional support.

Reporting

The ALS Scholars will submit semi-annual financial and scientific progress reports to the Healey & AMG Center who will share with funding partners. The ALS Scholars will also attend and present their findings at least one of the semi-annual Healey & AMG Science Advisory Council and ALSFAC meetings during the funding period.

Application Due Dates

Applications Due: January 15, 2025

Notification of Award: May 2025

Initiation of Award*: July 1, 2025 (flexible once contracts signed)

Please submit your application through our new application portal here.

For queries contact: email hidden; JavaScript is required


The Harvard/Partners Neurodegeneration Clinical Research (NCR) Fellowship is designed to produce experts in the field of neurodegenerative diseases and clinical research, with a particular focus on the clinical care and research of neurodegenerative disease, who will shape clinical research in these fields throughout their career.

The Neurodegeneration Clinical Research Fellowship training will occur via two major avenues: 1) Clinical Care training conducted primarily through mentored clinical encounters and supplemented by clinical conferences and individual study; and 2) Clinical Research training conducted through the experience of acting as a sub-investigator on at least one non-interventional research project and at least one treatment trial, as well as the development of one unique clinical research project with the careful support of a research mentor.

Eligibility/Application Process

Candidates must be board-eligible in Neurology, have completed residency in good standing prior to the start of the fellowship, and have a strong interest in clinical research. Candidates may have completed a one year neuromuscular fellowship or equivalent prior to joining this fellowship.

For more information on the Neurodegenerative Clinical Research Fellowship, and how to apply, please view the fellowship website (https://www.mgbneurologyfellowships.org/fellowships/neurodegenerative.htmlcontact) and contact Program Director, email hidden; JavaScript is required.


The CTMC seeks applications from investigators who are from diverse backgrounds, from across various institutions, or performing research in diverse neurological disease populations, including pediatric patients, underrepresented groups, and rare diseases.

The 2025 CTMC will include 2 tracks:

  • Foundation track: The foundation track is for investigators who have not previously designed their own prospective, interventional clinical trial. Most applications received by the CTMC will fit into the foundation track. Projects in this track will typically be single-center and early phase. The course is best suited for clinical trials that deliver one or more interventions (may include placebo or other control) in prospective manner to human participants with a neurological condition to evaluate the outcome of the interventions.
  • Advanced track: The advanced track is for investigators who are proposing a large, multi-center phase 2/3 trial. Investigators in the advanced track will typically have prior clinical trials experience as a site PI or co-investigator, although for some rare or pediatric diseases, a multi-center trial may be required for the initial trial. Projects in the advanced track should be suited for one of the NINDS research networks (SIREN, StrokeNet, NeuroNEXT).

Course Information:

The CTMC includes a combination of virtual and in-person activities. Virtual webinars and small group mentorship meetings will take place weekly between March – July 2025. The in-person, residential part of the course will be held June 23 – 26 in Charlottesville, VA. Attendance at the residential course is required; funding for travel (within the US) and accommodations will be provided for participants. Learn more about the course schedule and time requirements on our website.

We will host an informational webinar on December 19, 2024, at 1:00pm Eastern Time to provide more guidance and answer questions about the course and application process. Register to attend the webinar here; a recording will be added to our website after the session.

For those who are unable to participate in the 2025 course, the course webinars are open sessions that anyone can attend; more information will be posted on the website in spring 2025.

Application & Deadline:

The application deadline for 2025 is January 21 at 11:59pm Pacific Standard Time.

Questions?

Please refer to the FAQ on our website. You are welcome to contact us at email hidden; JavaScript is required or email hidden; JavaScript is required with any additional questions.

Thank you,

CTMC Executive Committee

MDA provides support for research throughout the pipeline of drug development from discovery research through clinical trials. Funding opportunities exist for both academic investigators as well as for biotech and pharma seeking to develop therapies for neuromuscular disease.

Learn about all our grant programs and find deadlines and instructions on how to apply.